Abstract:AIM:To investigate the impact of minimum tacrolimus (TAC) on new-onset diabetes mellitus (NODM) after liver transplantation (LT). METHODS:We retrospectively analyzed the data of 973 liver transplant recipients between March 1999 and September 2014 in West China Hospital Liver Transplantation Center. Following the exclusion of ineligible recipients, 528 recipients with a TAC-dominant regimen were included in our study. We calculated and determined the mean trough concentration of TAC (cTAC) in the year of diabetes diagnosis in NODM recipients or in the last year of the follow-up in non-NODM recipients. A cutoff of mean cTAC value for predicting NODM 6 mo after LT was identified using a receptor operating characteristic curve. TAC-related complications after LT was evaluated by χ(2) test, and the overall and allograft survival was evaluated using the Kaplan-Meier method. Risk factors for NODM after LT were examined by univariate and multivariate Cox regression. RESULTS:Of the 528 transplant recipients, 131 (24.8%) developed NODM after 6 mo after LT, and the cumulative incidence of NODM progressively increased. The mean cTAC of NODM group recipients was significantly higher than that of recipients in the non-NODM group (7.66 ± 3.41 ng/mL vs 4.47 ± 2.22 ng/mL, P < 0.05). Furthermore, NODM group recipients had lower 1-, 5-, 10-year overall survival rates (86.7%, 71.3%, and 61.1% vs 94.7%, 86.1%, and 83.7%, P < 0.05) and allograft survival rates (92.8%, 84.6%, and 75.7% vs 96.1%, 91%, and 86.1%, P < 0.05) than the others. The best cutoff of mean cTAC for predicting NODM was 5.89 ng/mL after 6 mo after LT. Multivariate analysis showed that old age at the time of LT (> 50 years), hypertension pre-LT, and high mean cTAC (≥ 5.89 ng/mL) after 6 mo after LT were independent risk factors for developing NODM. Concurrently, recipients with a low cTAC (< 5.89 ng/mL) were less likely to become obese (21.3% vs 30.2%, P < 0.05) or to develop dyslipidemia (27.5% vs 44.8%, P <0.05), chronic kidney dysfunction (14.6% vs 22.7%, P < 0.05), and moderate to severe infection (24.7% vs 33.1%, P < 0.05) after LT than recipients in the high mean cTAC group. However, the two groups showed no significant difference in the incidence of acute and chronic rejection, hypertension, cardiovascular events and new-onset malignancy. CONCLUSION:A minimal TAC regimen can decrease the risk of long-term NODM after LT. Maintaining a cTAC value below 5.89 ng/mL after LT is safe and beneficial.

Cyclosporine Minimization Decreases The Risk Of Post-Transplantation Diabetes Mellitus: 10-Year Single Center Experience In West China

Minimizing Tacrolimus Decreases the Risk of New-Onset Diabetes Mellitus after Liver Transplantation

Reduced-Dose Cyclosporine with Mycophenolate Mofetil and Prednisone Significantly Improves the Long-Term Glomerular Filtration Rate and Graft Survival

''Minimizing tacrolimus'' strategy and long-term survival after liver transplantation.

Improved Clinical Outcomes in Chinese Renal Allograft Recipients Receiving Lower Dose Immunosuppressants

Higher Tacrolimus Blood Concentration is Related to Increased Risk of Post-Transplantation Diabetes Mellitus after Living Donor Liver Transplantation

Clinical Analysis of 2520 Renal Transplantations in One Center

Long-term outcomes of kidney transplantation in 2332 patients under cyclosporine A

Assessment of Cyclosporine A Withdrawal in Renal Allograft Transplant Recipients

Cyclosporine A and Tacrolimus Combined with Enteric-Coated Mycophenolate Sodium Influence the Plasma Mycophenolic Acid Concentration - a Randomised Controlled Trial in Chinese Live Related Donor Kidney Transplant Recipients

Effect of Low-Dose Tacrolimus with Mycophenolate Mofetil on Renal Function Following Liver Transplantation.

Calcineurin-Inhibitor Minimization In Liver Transplant Patients With Calcineurin-Inhibitor-Related Renal Dysfunction: A Meta-Analysis

Prophylaxis of Chronic Kidney Disease after Liver Transplantation - Experience from West China

Two Different Doses of Cyclosporine for Patients After Renal Transplantation:Clinical Controlled Study

Incidence, clinical classification and risk factors of cyclosporin A‐induced liver injury in allogeneic haematopoietic stem cell transplant recipients

Role of Steroid Minimization in the Tacrolimus-Based Immunosuppressive Regimen for Liver Transplant Recipients: a Systematic Review and Meta-Analysis of Prospective Randomized Controlled Trials.

Outcomes of Standard Dose EC-MPS with Low Exposure to CsA in DCD Renal Transplantation Recipients with DGF.

[Mycophenolate Mofetil-Based Calcineurin Inhibitor Reduced Immunosuppressive Protocol for the Improvement of Renal Dysfunction after Liver Transplantation].

Optimal Sampling Time-Point for Cyclosporin A Concentration Monitoring in Heart Transplant Recipients.

A clikical study on kidney transplantation patients with a survival time over 10 years and long-term administration of cyclosporine

Efficacy and Safety of a Reduced Calcineurin Inhibitor Dose Combined with Mycophenolate Mofetil in Liver Transplant Patients with Chronic Renal Dysfunction.